TrialHepatology (Baltimore, Md.)2015

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

David R Nelson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.